IL260229B2 - Suspension formulations of st-246 (tecovirimate monohydrate) - Google Patents
Suspension formulations of st-246 (tecovirimate monohydrate)Info
- Publication number
- IL260229B2 IL260229B2 IL260229A IL26022918A IL260229B2 IL 260229 B2 IL260229 B2 IL 260229B2 IL 260229 A IL260229 A IL 260229A IL 26022918 A IL26022918 A IL 26022918A IL 260229 B2 IL260229 B2 IL 260229B2
- Authority
- IL
- Israel
- Prior art keywords
- dry suspension
- suspension according
- formulation
- methylcellulose
- dry
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295710P | 2016-02-16 | 2016-02-16 | |
| PCT/US2017/017915 WO2017142910A1 (en) | 2016-02-16 | 2017-02-15 | St-246 ( tecovirimat monohydrate) suspension formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL260229A IL260229A (en) | 2018-07-31 |
| IL260229B2 true IL260229B2 (en) | 2023-06-01 |
Family
ID=59625432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL260229A IL260229B2 (en) | 2016-02-16 | 2018-06-24 | Suspension formulations of st-246 (tecovirimate monohydrate) |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11433051B2 (enExample) |
| EP (1) | EP3416637B1 (enExample) |
| JP (2) | JP7074677B2 (enExample) |
| CN (1) | CN108430469A (enExample) |
| AU (2) | AU2017221295B2 (enExample) |
| CA (1) | CA3013937A1 (enExample) |
| FI (1) | FI3416637T3 (enExample) |
| IL (1) | IL260229B2 (enExample) |
| WO (1) | WO2017142910A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7074677B2 (ja) * | 2016-02-16 | 2022-05-24 | シガ・テクノロジーズ・インコーポレーテッド | Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤 |
| EP4755373A1 (en) * | 2016-09-09 | 2026-06-10 | Azurity Pharmaceuticals, Inc. | Suspensions and diluents for metronidazole and baclofen |
| CN115141136B (zh) * | 2021-03-31 | 2023-06-20 | 中国人民解放军军事科学院军事医学研究院 | 特考韦瑞药的共晶及其制备方法 |
| CN114432241B (zh) * | 2021-12-21 | 2023-07-14 | 上海奥全生物医药科技有限公司 | 一种快速分散的助悬组合物、制备方法及其应用 |
| CN116625971B (zh) * | 2023-04-11 | 2026-04-17 | 北京达因高科儿童药物研究院有限公司 | 一种西甲硅油口溶膜中二甲硅油和二氧化硅含量的检测方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011360A (zh) * | 2007-02-05 | 2007-08-08 | 深圳致君制药有限公司 | 干混悬剂的处方组成及其制备方法 |
| CN102406617A (zh) * | 2011-11-30 | 2012-04-11 | 中国人民解放军军事医学科学院生物工程研究所 | 一种替韦立马干混悬剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3043747A (en) * | 1958-10-22 | 1962-07-10 | Upjohn Co | Tablets coated with carboxymethylcellulose shellac composition |
| US4863737A (en) * | 1985-05-01 | 1989-09-05 | University Of Utah | Compositions and methods of manufacture of compressed powder medicaments |
| ES2043766T3 (es) * | 1987-11-11 | 1994-01-01 | Pharmascience Lab | Una nueva composicion farmaceutica que comprende exifona y un polimero soluble en agua. |
| FR2705966B1 (fr) * | 1993-06-04 | 1995-08-25 | Dow Corning Sa | Compositions antimousse utiles notamment pour le traitement de troubles gastriques. |
| PE20170944A1 (es) * | 2010-03-23 | 2017-07-13 | Siga Tech Inc | Formas polimorficas de st-246 y metodos de preparacion |
| CN102532901A (zh) | 2010-12-21 | 2012-07-04 | 重庆北碚现代应用药物研究所 | 一种西甲硅油的制备方法 |
| CN105055326B (zh) | 2015-07-17 | 2018-02-06 | 西南大学 | 西甲硅油干混悬剂及其制备方法 |
| JP7074677B2 (ja) * | 2016-02-16 | 2022-05-24 | シガ・テクノロジーズ・インコーポレーテッド | Ｓｔ－２４６（テコビリマット一水和物）懸濁製剤 |
-
2017
- 2017-02-15 JP JP2018542140A patent/JP7074677B2/ja active Active
- 2017-02-15 EP EP17753732.1A patent/EP3416637B1/en active Active
- 2017-02-15 WO PCT/US2017/017915 patent/WO2017142910A1/en not_active Ceased
- 2017-02-15 AU AU2017221295A patent/AU2017221295B2/en active Active
- 2017-02-15 CN CN201780005245.5A patent/CN108430469A/zh active Pending
- 2017-02-15 FI FIEP17753732.1T patent/FI3416637T3/fi active
- 2017-02-15 CA CA3013937A patent/CA3013937A1/en active Pending
- 2017-02-15 US US16/071,119 patent/US11433051B2/en active Active
-
2018
- 2018-06-24 IL IL260229A patent/IL260229B2/en unknown
-
2021
- 2021-12-13 JP JP2021201709A patent/JP7297858B2/ja active Active
-
2022
- 2022-07-14 US US17/864,909 patent/US11779566B2/en active Active
- 2022-08-18 AU AU2022218556A patent/AU2022218556B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101011360A (zh) * | 2007-02-05 | 2007-08-08 | 深圳致君制药有限公司 | 干混悬剂的处方组成及其制备方法 |
| CN102406617A (zh) * | 2011-11-30 | 2012-04-11 | 中国人民解放军军事医学科学院生物工程研究所 | 一种替韦立马干混悬剂及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| YANG G ET AL., AN ORALLY BIOAVAILABLE ANTIPOXVIRUS COMPOUND (ST-246) INHIBITS EXTRACELLULAR VIRUS FORMATION AND PROTECTS MICE FROM LETHAL ORTHOPOXVIRUS CHALLENGE, 31 October 2005 (2005-10-31) * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3013937A1 (en) | 2017-08-24 |
| JP7074677B2 (ja) | 2022-05-24 |
| AU2017221295A1 (en) | 2018-07-12 |
| JP2022031345A (ja) | 2022-02-18 |
| IL260229A (en) | 2018-07-31 |
| US20230016581A1 (en) | 2023-01-19 |
| JP2019511465A (ja) | 2019-04-25 |
| US20210212987A1 (en) | 2021-07-15 |
| AU2017221295B2 (en) | 2022-05-19 |
| AU2022218556A1 (en) | 2022-09-15 |
| WO2017142910A1 (en) | 2017-08-24 |
| CN108430469A (zh) | 2018-08-21 |
| EP3416637A4 (en) | 2019-11-06 |
| EP3416637A1 (en) | 2018-12-26 |
| US11779566B2 (en) | 2023-10-10 |
| US11433051B2 (en) | 2022-09-06 |
| AU2022218556B2 (en) | 2024-08-15 |
| JP7297858B2 (ja) | 2023-06-26 |
| EP3416637B1 (en) | 2026-06-10 |
| FI3416637T3 (fi) | 2026-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120142741A1 (en) | Pharmaceutical compositions for the treatment of cancer | |
| US20100247647A1 (en) | Sustained release tablets with hydromorphone | |
| EP3417861A1 (en) | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof | |
| HUE029299T2 (en) | Preparations for delivery of adsorbents to the intestine by mouth | |
| JP2023513249A5 (enExample) | ||
| JP2018502928A (ja) | 分散性組成物 | |
| EP2740471B1 (en) | Oral pharmaceutical composition comprising dabigatran etexilate | |
| WO2015031228A1 (en) | Oral pharmaceutical formulation of omarigliptin | |
| EP2902016A1 (en) | Febuxostat tablet | |
| JP2019511465A5 (enExample) | ||
| JP2016518398A (ja) | 低用量医薬組成物 | |
| EP3793530A1 (en) | Solid dispersion containing ritonavir | |
| CN104363896A (zh) | 恩替卡韦的药物组合物及制造方法 | |
| JP2000355540A (ja) | 安定化したベンズイミダゾール系化合物含有組成物 | |
| EP2641594B1 (en) | Enteric coated solid pharmaceutical compositions for proton pump inhibitors | |
| EP2366379A1 (en) | Cefdinir formulation with improved dissolution rate | |
| WO2012108631A2 (en) | Pharmaceutical compositions comprising revaprazan-containing nanoparticles and processes for the preparation thereof | |
| JP2019535696A (ja) | ピリドン誘導体の医薬組成物およびその製造方法 | |
| EP2723322A1 (en) | Imatinib mesylate oral pharmaceutical composition and process for preparation thereof | |
| WO2013151518A1 (en) | Capsule formulations comprising ceftibuten | |
| EP3143991A1 (en) | Fingolimod capsule composition | |
| KR101578627B1 (ko) | 실로도신의 용출 특성이 향상된 약제학적 제제 | |
| WO2011086577A2 (en) | Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts | |
| US20080206348A1 (en) | Cilostazol-Containing Pharmaceutical Composition Based On Particles Of Less Than 50 Micrometers | |
| JP5034226B2 (ja) | 配合成分が安定化された固形製剤 |